
Evaxion narrows Q3 loss to $3.5 million
Key points
- Evaxion (NASDAQ:EVAX) reported a third-quarter 2026 net loss of US$3.5 million, compared with net income of US$4.6 million a year earlier.
- Quarterly revenue fell to zero from US$7.492 million, while share sales generated US$2.2 million in gross proceeds.
- The company is prioritizing cancer vaccine development, with a Phase I trial application for EVX-04 targeted by the end of 2026.
Evaxion (NASDAQ:EVAX) reported a third-quarter 2026 net loss of US$3.5 million, compared with net income of US$4.6 million in the same period last year, as it refocused its research activities on cancer vaccines.
Quarterly revenue fell to zero from US$7.492 million a year earlier, although the net loss narrowed from US$3.7 million in the second quarter of 2026.
The company reported that its personalized cancer vaccine candidate EVX-01 demonstrated 89% vaccine target precision in a Phase II advanced melanoma study, with sustained immune and clinical responses observed at the three-year follow-up.
Evaxion raised US$2.2 million in gross proceeds from share sales and expects its available cash to fund operations toward the end of 2027.
Evaxion said it remains on track to file a Phase I clinical trial application for EVX-04 by the end of 2026 and plans to advance another cancer vaccine candidate, EVX-05, toward clinical development.
The company is making cancer vaccines its primary research focus, while further development of its infectious disease programmes will depend on securing external partner funding.


